Integragen
IntegraGen SA provides researchers with sequencing solutions, data management tools, and biostatistical, and bioinformatics support services in France. The company's genomic pharma services DNA sequencing for oncology and rare disease research; and NGS testing for cancer research. It also provides MERCURY, an online biological interpretation tool for oncology intended to assist pathologists and o… Read more
Integragen (ALINT) - Total Assets
Latest total assets as of June 2025: €3.60 Million EUR
Based on the latest financial reports, Integragen (ALINT) holds total assets worth €3.60 Million EUR as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Integragen - Total Assets Trend (2008–2024)
This chart illustrates how Integragen’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Integragen - Asset Composition Analysis
Current Asset Composition (December 2024)
Integragen's total assets of €3.60 Million consist of 95.4% current assets and 4.6% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 34.5% |
| Accounts Receivable | €3.16 Million | 57.2% |
| Inventory | €205.00K | 3.7% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2008–2024)
This chart illustrates how Integragen's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Integragen's current assets represent 95.4% of total assets in 2024, a decrease from 96.7% in 2008.
- Cash Position: Cash and equivalents constituted 34.5% of total assets in 2024, up from 1.4% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 59.0% in 2008.
- Asset Diversification: The largest asset category is accounts receivable at 57.2% of total assets.
Integragen Competitors by Total Assets
Key competitors of Integragen based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Integragen - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Integragen generates 1.58x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Integragen is currently not profitable relative to its asset base.
Integragen - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.19 | 1.53 | 1.49 |
| Quick Ratio | 1.10 | 1.44 | 1.41 |
| Cash Ratio | 0.00 | 0.00 | 0.81 |
| Working Capital | €549.37K | € 2.07 Million | € 2.82 Million |
Integragen - Advanced Valuation Insights
This section examines the relationship between Integragen's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.49 |
| Latest Market Cap to Assets Ratio | 0.08 |
| Asset Growth Rate (YoY) | -31.1% |
| Total Assets | €5.51 Million |
| Market Capitalization | $424.10K USD |
Valuation Analysis
Below Book Valuation: The market values Integragen's assets below their book value (0.08 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Integragen's assets decreased by 31.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Integragen (2008–2024)
The table below shows the annual total assets of Integragen from 2008 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €5.51 Million | -31.07% |
| 2023-12-31 | €8.00 Million | -11.33% |
| 2022-12-31 | €9.02 Million | -6.05% |
| 2021-12-31 | €9.60 Million | +8.87% |
| 2020-12-31 | €8.82 Million | +30.74% |
| 2019-12-31 | €6.75 Million | -21.38% |
| 2018-12-31 | €8.58 Million | -0.77% |
| 2017-12-31 | €8.65 Million | +13.96% |
| 2016-12-31 | €7.59 Million | -11.95% |
| 2015-12-31 | €8.62 Million | -6.00% |
| 2014-12-31 | €9.17 Million | +58.55% |
| 2013-12-31 | €5.78 Million | -26.36% |
| 2012-12-31 | €7.85 Million | +12.73% |
| 2011-12-31 | €6.97 Million | -14.82% |
| 2010-12-31 | €8.18 Million | +95.36% |
| 2009-12-31 | €4.19 Million | +17.07% |
| 2008-12-31 | €3.58 Million | -- |